Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Quantitative gene-expression of the tumor angiogenesis markers vascular endothelial growth factor, integrin alphaV and integrin beta3 in human neuroendocrine tumors

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Mismatch repair gene mutation spectrum in the Swedish Lynch syndrome population

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Genomic profiling of a combined large cell neuroendocrine carcinoma of the submandibular gland

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Genetic analysis of an orbital metastasis from a primary hepatic neuroendocrine carcinoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. CRTC1-MAML2 gene fusion in mucoepidermoid carcinoma of the lacrimal gland

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Genetic profiles distinguish different types of hereditary ovarian cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Cardiac Autonomic Function is Associated With Myocardial Flow Reserve in Type 1 Diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Hyperpolarized 13C MRI: Path to Clinical Translation in Oncology

    Research output: Contribution to journalReviewResearchpeer-review

  4. Feasibility of multi-parametric PET and MRI for prediction of tumour recurrence in patients with glioblastoma

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Anti-angiogenesis treatment is a promising new therapy for cancer that recently has also been suggested for patients with neuroendocrine tumors. The aim of the present study was therefore to investigate the level of tumor angiogenesis, and thereby the molecular basis for anti-angiogenesis treatment, in neuroendocrine tumors. We used quantitative real-time PCR for measuring mRNA gene-expression of vascular endothelial growth factor (VEGF), integrin alphaV, and integrin beta3, and CD34 for a group of patients with neuroendocrine tumors (n=13). Tissue from patients with colorectal cancer liver metastases (n=14) and normal liver tissues (n=16) was used as control. We found a lower mRNA level of VEGF in neuroendocrine tumors compared to both colorectal liver metastases (p<0.001) and normal liver tissue (p<0.01). For integrin beta3 there was also a borderline significant lower level of mRNA in neuroendocrine tumors compared to both colorectal liver metastases (p=0.10) and normal liver tissue (p=0.06). In neuroendocrine tumors, gene-expression was highly variable of VEGF (530-fold), integrin alphaV (23-fold) and integrin beta3 (106-fold). Quantitative gene-expression levels of the key angiogenesis molecules VEGF and integrin beta3 were lower in neuroendocrine tumors than in colorectal liver metastases and were highly variable. Therefore, individual selection of patients may be necessary if anti-angiogenesis treatment is to be successful in patients with neuroendocrine tumors.

Original languageEnglish
JournalOncology Reports
Volume21
Issue number3
Pages (from-to)769-75
Number of pages7
ISSN1021-335X
Publication statusPublished - Mar 2009

    Research areas

  • Adolescent, Adult, Aged, Antigens, CD34, Colorectal Neoplasms, Female, Gene Expression, Gene Expression Profiling, Humans, Integrin alphaV, Integrin beta3, Liver Neoplasms, Male, Middle Aged, Neovascularization, Pathologic, Neuroendocrine Tumors, RNA, Messenger, Reverse Transcriptase Polymerase Chain Reaction, Vascular Endothelial Growth Factor A

ID: 44962714